Stock Comparison

IVVD vs JNJ

Invivyd Inc vs Johnson & Johnson

The Verdict

IVVD takes this one.

Winner

IVVD

Invivyd Inc

7.5

out of 10

Solid Pick

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$406M

Market Cap

N/A

-3.7

P/E Ratio

N/A

-98.2%

Profit Margin

N/A

-67.9%

Return on Equity

N/A

0.0

Debt-to-Equity

N/A

Aggressive

Overall Risk

Conservative

7.5

DVR Score

1.0

The Deep Dive

IVVD7.5/10

Invivyd (IVVD) presents a compelling high-risk, high-reward opportunity, demonstrating significant improvement since our last analysis. The reported Q4 2025 earnings (March 5, 2026) were a major catalyst, showcasing a substantial revenue beat ($17.2M actual vs. $15.77M est.), a 31% sequential growth for PEMGARDA, and a remarkable 110% YoY revenue increase for FY 2025 to $53.4M. Critically, Q4 2025...

Full IVVD Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.